NIKKEI 225
39,631.06 +47.98 (+0.12%) HANG SENG
17,718.61 +2.11 (+0.01%) CRUDE OIL
83.40 +0.02 (+0.02%) GOLD FUTURES
2,341.50 +2.60 (+0.11%) DOW
39,169.52 +50.66 (+0.13%) Bitcoin GBP
49,623.10 +179.57 (+0.36%)
IMNM Jan 2025 30.000 call
| Previous close | 0.7000 |
| Open | 0.7000 |
| Bid | 0.0000 |
| Ask | 1.9000 |
| Strike | 30.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.7000 - 0.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | 16 |
Business WireImmunome Appoints Phil Tsai as Chief Technical Officer
BOTHELL, Wash., June 27, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Tsai, PhD, as Chief Technical Officer. Dr. Tsai has nearly three decades of experience in product development, process optimization, and manufacturing, particularly in the area of antibody-drug conjugates (ADCs).
GuruFocus.comInsider Buying: Immunome Inc's CEO Acquires 100,000 Shares
On May 21, 2024, Clay Siegall, President and Chief Executive Officer of Immunome Inc (NASDAQ:IMNM), purchased 100,000 shares of the company, as reported in a recent SEC Filing.
Business WireImmunome Announces Completion of Purchase of Assets from Atreca
BOTHELL, Wash., May 20, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the completion of its purchase of antibodies and related assets from Atreca, Inc. Under the terms of the agreement, Immunome paid Atreca $5.5 million upfront, and Atreca will be eligible for up to $7.0 million in clinical development milestones. Immunome received the rights to 28 antibodies as well as certain materi
